What’s new

• Mankind guided for at least double-digit revenue growth in FY27.
• Targets FY27 EBITDA margin of 25.5-26.5%.
• Plans to repay ₹2,500 cr of acquisition debt, targeting net debt/EBITDA of 0.5x.

Why it matters

The debt-repayment target is the clearest signal. Repaying ₹2,500 crore in one fiscal year is aggressive for a company of this size, and it suggests Mankind views the acquisition debt as a drag it wants to clear fast. The cautious GLP-1 stance is the opposite of the land-grab strategy peers are pursuing, which caps near-term upside but also the cash burn.

What we’re watching

• Actual FY27 debt-repayment versus the ₹2,500 cr plan.
• GLP-1 launch timing and initial pricing in India.
• Chronic-therapy share, which now sits at 39% of domestic revenue.

The full read

Mankind Pharma's FY27 playbook is defined by a clear trade-off: it will chase profit over the GLP-1 land grab, and it will use the cash to slash debt. Management guided for at least double-digit revenue growth and an EBITDA margin of 25.5-26.5% in FY27. The bigger commitment is to repay ₹2,500 crore of acquisition-related debt in a single year, targeting a net debt/EBITDA of 0.5x. That would effectively erase the acquisition's financing overhang. On the GLP-1 front, the company is deliberately staying on the sidelines, focusing on profitability rather than spending heavily for volume. The chronic-therapy mix is moving in the right direction, now at 39% of domestic sales, up 190 bps year-on-year. The core bet is that financial deleveraging and a disciplined margin profile will matter more than top-line share in a new therapeutic class.

Primary source: BSE · NSE